Reaction
Erythrodermic Psoriasis reporting signals
As of the last recalculation, Erythrodermic Psoriasis appears in 807 FAERS reports alongside 17 co-occurring drug terms. The strongest observed disproportionality signal is ADALIMUMAB-AATY (PRR 26.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Adalimumab-Aaty | 46 | 26.5 | 26.5 |
| Adalimumab-Fkjp | 45 | 26.5 | 26.5 |
| Adalimumab-Adaz | 46 | 23.8 | 23.8 |
| Ustekinumab | 84 | 23.5 | 23.5 |
| Clobetasol Propionate Ointment Usp, 0.05% | 9 | 22.8 | 22.8 |
| Clobetasol Propionate | 9 | 22.7 | 22.7 |
| Cyclosporine | 83 | 21.3 | 21.3 |
| Isoniazid | 13 | 21.0 | 21.0 |
| Terbinafine Hydrochloride | 7 | 20.5 | 20.5 |
| Baricitinib | 7 | 18.9 | 18.9 |
| Diltiazem Hydrochloride Extended-Release Tablets | 8 | 18.3 | 18.3 |
| Ceftriaxone | 19 | 15.3 | 15.3 |
| Secukinumab | 75 | 13.1 | 13.1 |
| Ixekizumab | 17 | 12.1 | 12.1 |
| Daptomycin | 4 | 11.2 | 11.2 |
| Guselkumab | 15 | 11.0 | 11.0 |
| Apremilast | 19 | 3.4 | 3.4 |